Gabriela Morales-Rivera

Gabriela Morales-Rivera is a partner in the firm's Business Law department and a member of its Technology and Life Sciences groups. Gabriela represents public and private companies in startup and formation matters, venture capital financing, initial public offerings and capital markets transactions, strategic investments, and other complex transactions.

She also represents a number of publicly traded biotechnology companies in ongoing SEC compliance and corporate governance matters. Advising companies throughout the full range of the corporate life cycle, Gabriela has worked with many of her company-side clients since their initial founding and funding. She joined Goodwin in 2015.

Gabriela's recent client representations include the following:

General Corporate Counseling and Significant Transactions

• Relay Therapeutics in connection with:
  • its $63 million Series B financing
  • its $400 million Series C financing
  • its $460 million initial public offering
  • its collaboration and license agreement with Genentech for the development and commercialization of RLY-1971
  • its acquisition of ZebiAI for $85 million upfront
  • its $350 million follow-on offering
  • its $300 million “at-the-market” offering
  • Its $300 million follow-on offering
• Forma Therapeutics in connection with:
  • its $100 million Series D financing
  • its $319.3 million initial public offering
  • its $275.8 million follow-on offering
  • its $200 million “at-the-market” offering
  • Its $1.1 billion sale to Novo Nordisk
• Nimbus Therapeutics in connection with:
  • the $1.2 billion sale of its ACC inhibitor program to Gilead Bioscience
  • its multi-target strategic alliance with Celgene Corporation in immunology
  • its $65 million Series 2018 preferred financing
  • its $43 million Series B financing
  • its $60 million private financing round from life science investors RA Capital Management and BVF Partners L.P.
  • its $105 million private financing
  • Its $125.0 million private financing
• ElevateBio in connection with:
  • its $150 million Series A financing
  • its $193 million Series B financing
  • its $525 million Series C financing
• Akero Therapeutics in connection with:
  • its $65 million Series A financing
  • its $70 million Series B financing
  • its $105.8 million initial public offering
  • its $216.4 million follow-on public offering
  • Its $25.0 million equity investment by Pfizer Inc.
  • Its $100.0 million term loan facility with Hercules Capital, Inc.
  • Its $230.0 million follow-on public offering
• Accent Therapeutics $63.0 million Series B financing
• MoMa Therapeutics in its
  • $86.0 million Series A financing
  • $150.0 million Series B financing
• ROME Therapeutics in connection with:
  • its $50 million Series A financing
  • its $77 million Series B financing
• Aptinyx in connection with:
  • its $65 million Series A financing
  • its $70 million Series B financing
  • its $117.8 million initial public offering
• Allovir in its $120 million Series B financing
• Cullinan Oncology in its:
  • $98.5 million Series B Financing
  • $131.2 million Series C Financing
  • $287.4 million initial public offering
• Exosome Diagnostics in connection with:
  • its $30 million Series C financing
  • its sale to Bio-Techne Corporation
• Kymera Therapeutics in connection with:
  • its $30 million Series A financing
  • its $65 million Series B financing
  • its research and development collaboration with Vertex Pharmaceuticals
  • its $200 million initial public offering
• Neon Therapeutics in connection with:
  • its $106 million Series B financing
  • its $100 million initial public offering
  • its $97 million sale to BioNTech
• Tango Therapeutics in connection with:
  • its $55 million Series A financing
  • its $60 million Series B financing
  • its $40 million equity financing

Public Company Representation and Capital Markets Transactions

• Adicet Bio, Inc. (formerly resTORbio, Inc.) in connection with:
  • its $97.8 million initial public offering
  • its $50 million follow-on offering
  • its $152 million follow-on offering and concurrent private placement
  • its $100.6 million follow-on offering
• Intellia Therapeutics in connection with:
  • its $150 million follow-on offering
  • its $115 million follow-on offering
  • its expanded licensing agreement with Regeneron Pharmaceuticals
  • its $600 million follow-on offering
• Vigil Neuroscience in its connection with:
  • $91.1 million initial public offering
  • Its $75.0 million private placement financing
• Talaris Therapeutics in its $150 million initial public offering
• Cabaletta Bio in its $75 million “at-the-market” offering
• Sage Therapeutics in its $575 million and $345 million follow-on offering
• Repligen Corp. in connection with:
  • its acquisition of TangenX Technology Corporation
  • its acquisition of Spectrum, Inc.
  • its $138 million follow-on offering

While attending law school, Gabriela interned for the Honorable Juan R. Torruella of the First Circuit Court of Appeals.

Gabriela is a member of the Boston and American Bar Associations as well as the Hispanic National Bar Association.

Gabriela has been recognized by The Best Lawyers in America Ones to Watch for her work in Corporate and Technology Law and Life Sciences Practice 2022 and 2023.